CCM
Consonance Capital Management Portfolio holdings
AUM
$7.28M
This Quarter Return
-11.41%
1 Year Return
-42.86%
3 Year Return
+319.33%
5 Year Return
+899.35%
10 Year Return
–
AUM
$1.36B
AUM Growth
+$1.36B
(-27%)
Cap. Flow
-$263M
Cap. Flow
% of AUM
-19.32%
Top 10 Holdings %
Top 10 Hldgs %
76.48%
Holding
31
New
2
Increased
13
Reduced
4
Closed
7
Top Buys
| 1 |
AMRN
Amarin Corp
AMRN
|
$61M |
| 2 |
Exelixis
EXEL
|
$54.4M |
| 3 |
United Therapeutics
UTHR
|
$26M |
| 4 |
uniQure
QURE
|
$24.5M |
| 5 |
Myriad Genetics
MYGN
|
$21M |
Top Sells
| 1 |
Puma Biotechnology
PBYI
|
$106M |
| 2 |
NVRO
NEVRO CORP.
NVRO
|
$82.4M |
| 3 |
Pacific Biosciences
PACB
|
$81.8M |
| 4 |
NUVA
NuVasive, Inc.
NUVA
|
$77.3M |
| 5 |
Verastem
VSTM
|
$37.4M |
Sector Composition
| 1 | Healthcare | 99.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pacira BioSciences
PCRX
$1.2B
| $157M | 11.56% | 3,652,134 | – | – |
|
|
2
Exelixis
EXEL
$10.1B
| $131M | 9.61% | 6,645,113 +2,766,063 | +71% | +$54.4M |
|
|
AMRN
3
Amarin Corp
AMRN
$311M
| $129M | 9.46% | 9,450,763 +4,482,100 | +90% | +$61M |
|
4
Vanda Pharmaceuticals
VNDA
$279M
| $122M | 8.95% | 4,658,759 +215,000 | +5% | +$5.62M |
|
|
5
United Therapeutics
UTHR
$13.8B
| $120M | 8.81% | 1,100,597 +238,302 | +28% | +$26M |
|
6
Travere Therapeutics
TVTX
$1.56B
| $91.2M | 6.71% | 4,032,123 +117,941 | +3% | +$2.67M |
|
7
Corcept Therapeutics
CORT
$7.35B
| $83M | 6.1% | 6,211,964 +1,173,090 | +23% | +$15.7M |
|
8
Vericel Corp
VCEL
$1.83B
| $73.4M | 5.4% | 4,218,092 +50,000 | +1% | +$870K |
|
|
9
Myriad Genetics
MYGN
$593M
| $68.9M | 5.07% | 2,370,296 +723,966 | +44% | +$21M |
|
10
UroGen Pharma
URGN
$900M
| $65.3M | 4.8% | 1,515,422 | – | – |
|
|
LMNX
11
DELISTED
Luminex Corp
LMNX
| $55.5M | 4.08% | 2,402,787 +33,779 | +1% | +$781K |
|
|
12
uniQure
QURE
$896M
| $54.6M | 4.02% | 1,896,226 +851,161 | +81% | +$24.5M |
|
13
Karyopharm Therapeutics
KPTI
$61.7M
| $45.1M | 3.31% | 4,810,078 -17,000 | -0.4% | -$159K |
|
|
OXFD
14
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $33M | 2.42% | 2,579,784 +130,600 | +5% | +$1.67M |
|
|
SPPI
15
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $26M | 1.91% | 2,969,027 -2,860,851 | -49% | -$25M |
|
16
Savara
SVRA
$567M
| $23.4M | 1.72% | 3,093,690 | – | – |
|
|
17
Pacific Biosciences
PACB
$393M
| $18.2M | 1.34% | 2,455,114 -11,057,844 | -82% | -$81.8M |
|
18
Catalyst Pharmaceutical
CPRX
$2.52B
| $18.1M | 1.33% | 9,402,317 +3,357,598 | +56% | +$6.45M |
|
|
STML
19
DELISTED
Stemline Therapeutics, Inc.
STML
| $11M | 0.81% | 1,155,793 -1,591,405 | -58% | -$15.1M |
|
20
ADMA Biologics
ADMA
$4.12B
| $11M | 0.81% | 4,588,352 +49,057 | +1% | +$117K |
|
21
Carisma Therapeutics
CARM
$8.98M
| $10.7M | 0.79% | 7,523,296 | – | – |
|
22
ANI Pharmaceuticals
ANIP
$2.03B
| $6.44M | 0.47% | 142,943 | – | – |
|
23
Aurinia Pharmaceuticals
AUPH
$1.58B
| $68K | 0.01% | +10,000 | New | +$68K |
|
24
Innoviva
INVA
$1.29B
| – | – | -1,002,675 | Closed | -$15.3M |
|
|
25
Puma Biotechnology
PBYI
$254M
| – | – | -2,303,455 | Closed | -$106M |
|